Under the terms of the research collaboration extension, Sentia and Neurocrine will continue to work together to discover novel peptide antagonists targeting CRF and advance them to development candidate stage, after which Neurocrine would be solely responsible for all further development, manufacturing, regulatory and commercial activities. As part of the collaboration, Sentia will continue to receive committed research funding from Neurocrine to support discovery efforts. Sentia is eligible to receive milestone and royalty payments based on products developed from this collaboration.
“We are delighted to further extend this important collaboration focused on the discovery and development of novel peptide therapeutics to address HPA-driven diseases and other potential indications with disrupted CRF physiology” said
About Sentia Medical Sciences
Source:Sentia Medical Sciences Inc. info@sentiamedical.com www.sentiamedical.com
2024 GlobeNewswire, Inc., source